Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy.

ABSTRACT: Breast cancer (BC) is one of the most prevalent types of cancer worldwide with high morbidity and mortality rates. Treatment modalities include systemic therapy, in which chemotherapy is a major component in many cases. Several chemotherapeutic agents are used in combinations or as single agents with many adverse events occurring in variable frequencies. These events can be a significant barrier in completing the treatment regimens. Germline genomic variants are thought of as potential determinants in chemotherapy response and the development of side effects. Some pharmacogenomic studies were designed to explore germline variants that can be used as biomarkers for predicting developing toxicity or adverse events during chemotherapy in BC. In this review, we reassess and summarize the major

SUBMITTER: Al-Mahayri ZN 

PROVIDER: S-EPMC7174767 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature